This observation agrees with a human clinical trial study showing a significant decrease in serum sRANKL and soluble RANKL/OPG ratio among postmenopausal women with osteopenia after twelve-week tocotrienol administration 46. This evidence concerns the gene TNFRSF11B and Osteopenia.